Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 18/20 | 0.51 |
| ▸ | GIPR | P48546 | 5/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | GCG | P01275 | 2/20 | 0.43 |
| ▸ | GLP1R | P43220 | 2/20 | 0.42 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654012 | 0.92 | GCGR (0.49) | GCGRGIPR | |
| SCHEMBL2654147 | 0.90 | FFAR1 (0.48) | GCGRGIPRFFAR1FFAR4GCG | |
| SCHEMBL2654589 | 0.89 | GCGR (0.48) | GCGRGIPRFFAR1FFAR4 | |
| SCHEMBL2654697 | 0.88 | GCGR (0.55) | GCGRGIPRGCGGLP1RCHRM5 | |
| SCHEMBL2654049 | 0.86 | GCGR (0.47) | GCGRGIPR | |
| SCHEMBL2654790 | 0.85 | GCG (0.48) | GCGRGIPRGCGGLP1RCHRM5 | |
| SCHEMBL2654507 | 0.85 | GCGR (0.47) | GCGRGIPRGLP1R | |
| SCHEMBL2655892 | 0.85 | GCGR (0.46) | GCGRGIPRGCGGLP1RVIPR2 | |
| SCHEMBL2654059 | 0.85 | GCGR (0.50) | GCGRGIPRGCG | |
| SCHEMBL2655266 | 0.84 | GCG (0.55) | GCGRGIPRGCGGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |